HeadFirst is developing a saliva‑based diagnostic device that enables healthcare professionals to screen for concussions quickly and non‑invasively. The technology aims to simplify detection and treatment decisions by providing a rapid test that can be administered at point‑of‑care, leveraging a patent‑pending method to analyze biomarkers in saliva.
Funding
Funding not disclosed
Founders
Product
Problem
Concussion screening often requires time‑consuming neurological exams or imaging, which can delay diagnosis and limit on‑field assessment, especially in sports or emergency settings.
Solution
HeadFirst is developing a point‑of‑care device that analyzes concussion‑related biomarkers in a small saliva sample. The system uses a proprietary assay to detect molecular signatures associated with head injury, delivering results within minutes. By providing a non‑invasive, rapid test, the device enables clinicians, athletic trainers, and first responders to identify concussions early and initiate appropriate care without the need for specialized equipment.
Target Audience
Primary users are healthcare providers, athletic trainers, and emergency medical personnel who need fast, reliable concussion screening in the field or clinic.
Features
- Saliva collection cartridge requiring only a few microliters of sample
- Patent‑pending biomarker assay that quantifies concussion‑specific proteins and metabolites
- Integrated handheld analyzer with on‑device processing and result readout in under five minutes
- Cloud‑connected software for secure data storage, trend tracking, and optional integration with electronic health records
- Designed for use in clinical offices, sports sidelines, and emergency environments with minimal training